Search Results 1131-1140 of 16958 for monoclonal antibody

1. A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia - Mayo Clinic

   Subject who received any prior monoclonal antibodies against PD-1 or PD-L1 and/or any prior: Arm A only: ImiDs (eg, lenalidomide, thalidomide);; Arm B ...

2. Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer - Mayo Clinic

   Monoclonal antibodies =< 2 weeks; Radiation therapy =< 2 weeks; Anti-Her-2 or other "targeted" (e.g. mammalian target of rapamycin [mTOR]) therapy =< 2 weeks.

3. A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy - Mayo Clinic

   History of severe hypersensitivity reactions to any ingredient of study drug(s) (azacitidine, venetoclax or MGB453) or monoclonal antibodies (mAbs) and/or their ...

4. Oral AMXT 1501 Dicaprate in Combination With IV DFMO - Mayo Clinic

   Monoclonal antibodies: > 21 days must have elapsed from the infusion of last dose of antibody and toxicity related to antibody therapy must be recovered to ...

5. A Study of the Safety and Effectiveness of GS-5745 in Participants with Moderately to Severely Active Crohn's Disease - Mayo Clinic

   Treatment with any monoclonal antibody within 4 weeks of screening; History or evidence of colonic mucosal dysplasia; HIV, hepatitis B, hepatitis C, or ...

6. A Study to Evaluate Tazemetostat and Pembrolizumab to Treat Advanced Urothelial Carcinoma - Mayo Clinic

   Patients who have had a prior monoclonal antibody within 4 weeks prior to study day 1 are not eligible. Patients with a known additional malignancy that is ...

7. Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy - Mayo Clinic

   ... antibody). Signs of active herpes simplex type 1 or 2 or varicella within 4 ... Exposure to monoclonal antibodies, cytokines, growth factors, soluble ...

8. A Study to Evaluate the Effectiveness, Safety and Tolerability of Efgatigimod PH20 SC in Adults with Pemphigus - Mayo Clinic

   plasmapheresis/ plasma exchange, immunoadsorption, and IVIg. 5. Use of any monoclonal antibody (including rituximab or another anti-CD20 biologic) within 6 ...

9. A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (enrollment by invitation only) - Mayo Clinic

   Known severe allergic reactions to TCZ or other monoclonal antibodies. Active TB infection. Suspected active bacterial, fungal, viral, or other infection ...

10. Haemophilus b polysaccharide vaccine (intramuscular route, injection route) - Mayo Clinic

    Children who developed Hib disease when 24 months of age or older do not need to be immunized, since most children in this age group will develop antibodies ...